Cash and Investments Decrease to $120.3M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy RZLT?
Cash, cash equivalents and investments in marketable securities were $120.3M as of March 31, compared with $167.9M as of June 30, 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RZLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.300
Low
2.00
Averages
6.29
High
20.00
Current: 3.300
Low
2.00
Averages
6.29
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rezolute Reports Q3 Earnings Beat Expectations
- Earnings Beat: Rezolute reported a Q3 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company had $120.3 million in cash, cash equivalents, and marketable securities, down from $167.9 million as of June 30, 2025, reflecting pressure on the company's financial management.
- FDA Meeting Feedback: Despite receiving positive feedback from the FDA meeting, the market remains cautious about the prospects of its lead asset, leading analysts to maintain a
See More
Rezolute Presents New Data on Ersodetug Study Outcomes
- Glycemic Control Improvement: In the sunRIZE study, the ersodetug treatment group showed clinically relevant reductions of over 50% in average daily time in hypoglycemia, while the placebo group did not achieve statistical significance, indicating the drug's potential in improving glycemic control.
- Strong Treatment Continuity: During the open-label extension phase, all 59 participants opted to continue receiving ersodetug, with 57 attending regular study visits, demonstrating good tolerability and sustained efficacy of the drug in long-term use.
- Reduction in Background Therapy: The use of ersodetug has led to a significant decrease in standard treatments (e.g., diazoxide, somatostatin analogs) for many patients, showcasing the drug's effectiveness as a monotherapy.
- Positive FDA Interaction: Rezolute's meeting with the FDA acknowledged challenges with the study's primary endpoint and requested broader data submission for further evaluation, reflecting the company's confidence and efforts toward obtaining approval.
See More
Rezolute's Positive FDA Meeting Outcomes for sunRIZE Program
- FDA Meeting Outcomes: Rezolute's March 17, 2026 meeting with the FDA yielded positive feedback, as the agency did not outright dismiss the sunRIZE study despite it not meeting its primary endpoint, indicating interest in further review.
- Clinical Data Insights: The company presented summary results from the sunRIZE study, highlighting that behavioral factors may have confounded the primary endpoint's statistical significance, while significant improvements in time in hypoglycemia were observed via CGM monitoring, suggesting potential drug efficacy.
- Next Steps Encouraged: The FDA urged Rezolute to submit study reports and analysis datasets for independent evaluation, which could pave the way for a marketing application for sunRIZE, reflecting the agency's cautious approach to new therapies.
- Patient Needs Emphasized: During the meeting, the FDA and Rezolute discussed the profound impact of congenital hyperinsulinism on patients, underscoring the necessity for new treatment options and reflecting a shared commitment to improving patient care.
See More
Rezolute Shares Rise After Positive FDA Meeting Outcome
- Positive FDA Meeting Outcome: Rezolute's shares rose after a meeting with the U.S. FDA, which acknowledged the potential impact of behavioral factors on patients in studies, indicating possible support for ersodetug despite last year's primary endpoint failure.
- Clinical Trial Challenges: The FDA recognized the limitations of relying on self-monitored blood glucose metrics to measure hypoglycemia in the sunRIZE study, suggesting that Rezolute may need to optimize its research design moving forward.
- Market Application Prospects: The FDA encouraged Rezolute to submit study data for independent review, with a decision expected on whether the sunRIZE data will suffice for a marketing application or if additional data will be required, directly impacting the company's market strategy.
- CEO's Positive Remarks: CEO Nevan Charles Elam expressed strong encouragement from the meeting's outcome, emphasizing that the FDA did not outright dismiss sunRIZE for not meeting its primary endpoint, indicating hope for the company's future clinical development.
See More
Faruqi & Faruqi Investigates Investor Losses in Rezolute
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Rezolute, Inc., indicating that the company may face legal liabilities for significant investor losses.
- Investor Rights Protection: The firm encourages investors who suffered losses in Rezolute stock or options to contact partner Josh Wilson directly, highlighting its commitment to protecting investor rights.
- Reputation Impact: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its influence in securities law, which may negatively impact Rezolute's market reputation.
- Legal Consultation Access: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310), indicating that the firm provides accessible legal consultation channels for affected investors.
See More
Faruqi & Faruqi Investigates Investor Losses in Rezolute
- Stock Price Plunge: Rezolute, Inc.'s shares plummeted on December 11, 2025, due to disappointing results from its Phase 3 sunRIZE clinical trial, collapsing from approximately $10.94 to $0.90, representing an 85-90% drop, indicating strong investor disappointment in the company's prospects.
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Rezolute, encouraging investors who suffered significant losses to contact partner Josh Wilson directly to discuss their legal rights and possible remedies, highlighting the firm's commitment to investor rights.
- Clinical Trial Failure: Rezolute's lead drug candidate, ersodetug, failed to meet both primary and key secondary endpoints in its clinical trial, leading to a significant decline in market confidence regarding its future products, which adversely affects the company's overall valuation and investment appeal.
- Investor Loss Warning: Faruqi & Faruqi emphasizes its track record of recovering hundreds of millions for investors since 1995, showcasing its expertise in securities law and commitment to protecting investor rights, potentially attracting more affected investors seeking legal assistance.
See More
Rezolute Reports Q3 Earnings Beat Expectations
- Earnings Beat: Rezolute reported a Q3 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company had $120.3 million in cash, cash equivalents, and marketable securities, down from $167.9 million as of June 30, 2025, reflecting pressure on the company's financial management.
- FDA Meeting Feedback: Despite receiving positive feedback from the FDA meeting, the market remains cautious about the prospects of its lead asset, leading analysts to maintain a
See More
Rezolute Presents New Data on Ersodetug Study Outcomes
- Glycemic Control Improvement: In the sunRIZE study, the ersodetug treatment group showed clinically relevant reductions of over 50% in average daily time in hypoglycemia, while the placebo group did not achieve statistical significance, indicating the drug's potential in improving glycemic control.
- Strong Treatment Continuity: During the open-label extension phase, all 59 participants opted to continue receiving ersodetug, with 57 attending regular study visits, demonstrating good tolerability and sustained efficacy of the drug in long-term use.
- Reduction in Background Therapy: The use of ersodetug has led to a significant decrease in standard treatments (e.g., diazoxide, somatostatin analogs) for many patients, showcasing the drug's effectiveness as a monotherapy.
- Positive FDA Interaction: Rezolute's meeting with the FDA acknowledged challenges with the study's primary endpoint and requested broader data submission for further evaluation, reflecting the company's confidence and efforts toward obtaining approval.
See More
Rezolute's Positive FDA Meeting Outcomes for sunRIZE Program
- FDA Meeting Outcomes: Rezolute's March 17, 2026 meeting with the FDA yielded positive feedback, as the agency did not outright dismiss the sunRIZE study despite it not meeting its primary endpoint, indicating interest in further review.
- Clinical Data Insights: The company presented summary results from the sunRIZE study, highlighting that behavioral factors may have confounded the primary endpoint's statistical significance, while significant improvements in time in hypoglycemia were observed via CGM monitoring, suggesting potential drug efficacy.
- Next Steps Encouraged: The FDA urged Rezolute to submit study reports and analysis datasets for independent evaluation, which could pave the way for a marketing application for sunRIZE, reflecting the agency's cautious approach to new therapies.
- Patient Needs Emphasized: During the meeting, the FDA and Rezolute discussed the profound impact of congenital hyperinsulinism on patients, underscoring the necessity for new treatment options and reflecting a shared commitment to improving patient care.
See More
Rezolute Shares Rise After Positive FDA Meeting Outcome
- Positive FDA Meeting Outcome: Rezolute's shares rose after a meeting with the U.S. FDA, which acknowledged the potential impact of behavioral factors on patients in studies, indicating possible support for ersodetug despite last year's primary endpoint failure.
- Clinical Trial Challenges: The FDA recognized the limitations of relying on self-monitored blood glucose metrics to measure hypoglycemia in the sunRIZE study, suggesting that Rezolute may need to optimize its research design moving forward.
- Market Application Prospects: The FDA encouraged Rezolute to submit study data for independent review, with a decision expected on whether the sunRIZE data will suffice for a marketing application or if additional data will be required, directly impacting the company's market strategy.
- CEO's Positive Remarks: CEO Nevan Charles Elam expressed strong encouragement from the meeting's outcome, emphasizing that the FDA did not outright dismiss sunRIZE for not meeting its primary endpoint, indicating hope for the company's future clinical development.
See More
Faruqi & Faruqi Investigates Investor Losses in Rezolute
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Rezolute, Inc., indicating that the company may face legal liabilities for significant investor losses.
- Investor Rights Protection: The firm encourages investors who suffered losses in Rezolute stock or options to contact partner Josh Wilson directly, highlighting its commitment to protecting investor rights.
- Reputation Impact: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its influence in securities law, which may negatively impact Rezolute's market reputation.
- Legal Consultation Access: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310), indicating that the firm provides accessible legal consultation channels for affected investors.
See More
Faruqi & Faruqi Investigates Investor Losses in Rezolute
- Stock Price Plunge: Rezolute, Inc.'s shares plummeted on December 11, 2025, due to disappointing results from its Phase 3 sunRIZE clinical trial, collapsing from approximately $10.94 to $0.90, representing an 85-90% drop, indicating strong investor disappointment in the company's prospects.
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Rezolute, encouraging investors who suffered significant losses to contact partner Josh Wilson directly to discuss their legal rights and possible remedies, highlighting the firm's commitment to investor rights.
- Clinical Trial Failure: Rezolute's lead drug candidate, ersodetug, failed to meet both primary and key secondary endpoints in its clinical trial, leading to a significant decline in market confidence regarding its future products, which adversely affects the company's overall valuation and investment appeal.
- Investor Loss Warning: Faruqi & Faruqi emphasizes its track record of recovering hundreds of millions for investors since 1995, showcasing its expertise in securities law and commitment to protecting investor rights, potentially attracting more affected investors seeking legal assistance.
See More
